Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28540
Licensed Patent means Stanford's U.S. Patent Application, Serial Number 60/048,961 and U.S. CIP Patent Application, Serial Number 09/413,285.
Mitofusin genes and proteins are provided. As used herein, the term mitofusin indicates the Drosophila Fzo protein or any of its homologues from insects, other invertebrates, yeast, and vertebrates including mouse and humans. Motifusins are large predicted GTPases with a predicted trans-membrane domain, coiled-coil regions, and a C-terminal region showing a high pl characteristic of mitochondrial matrix proteins. The mitofusin Fzo is the first known protein mediator of mitochondrial fusion, and mediates developmentally regulated post-meiotic fusion of mitochondria in Drosophila spermatids.
60/048,961 (6,284,507): Mitofusin genes and encoded polypeptides are provided, including the Drosophila Fzo protein and its homologs from insects, other invertebrates, yeast, and vertebrates including mouse and humans. Motifusins are large predicted GTPases with a predicted trans-membrane domain, coiled-coil regions, and a C-terminal region showing a high pl characteristic of mitochondrial matrix proteins. The mitofusins are the first known protein mediator of mitochondrial fusion, and mediate developmentally regulated post-meiotic fusion of mitochondria. Missense mutations that after conserved residues required for GTP binding in other GTPases inhibit the in vivo fusogenic activity of Fzo but do not affect its localization.
IPSCIO Record ID: 1455
Evaluation of Anthrax-Toxoid (AT) delivery system for efficiency in generating immune responses directed against tumor tissues in a mouse model system.
Application of the AT delivery system to two murine tumor models.
DNA Delivery Systems
Evaluation of the AT system for efficiency of DNA expression.
Testing of AT system for generating immune responses for Listeria monocytogenes.
Testing of a human pathogen as a DNA vaccine target.
Persistent Viral Infections
Application of the AT system to the (Latent Cytomegalovirus) LCMV model in mice.
Therapy of immunodeficiency virus (SHIV) infected Rhesus macaques and hepatitis B infected non-human primates using the AT system.
U.S. Patent Number 5,591,631 (USSN 08/021,601), entitled, â€œAnthrax Toxin Fusion Proteins And Related Methodsâ€, Leppla et al., filed February 12, 1993, issued, January 7, 1997.
U.S. Patent Application Serial Number 08/082,849 (CIP of 08/021,601), entitled, â€œAnthrax Toxin Fusion Proteins And Related Methodsâ€, Leppla et al., filed June 25, 1993.
Patent Application Serial Number 60/025,270, entitled, â€œTargeting Antigens To The MHC Class I Processing Pathway With An Anthrax Toxin Fusion Proteinâ€, Klimpel et al., filed September 17, 1996.
IPSCIO Record ID: 28224
(a) an exclusive license in the Territory under the Licensed Technology to conduct research on, develop and commercialize the Licensed Technology, to manufacture, have manufactured, use and have used, market, sell, have sold, offer for sale, have offered for sale, import and export and have imported and exported the compositions, technology or inventions, and to practice (or practise) the processes or methods that are within or that constitute the Licensed Technology for use in the Field.
(b) the right to grant Sublicenses (with the right of such sublicensees to grant further sublicenses).
Licensed Technology means Improvements, Inventions, Information and Know-How and Patents.
Patents means :
(a) (i) Patent number 5,767,336 granted in the United States of America entitled 'Gene Trap Vectors Comprising a Type II Transmembrane Domain', issued August 4,
(ii) Patent number 5,789,653 granted in the United States of America entitled 'Secretary Gene Trap', issued June 16, 1998;
(iii) Patent number 673,650 granted in Australia entitled 'Novel Vectors and Use Thereof for Capturing Target Genes', issued March 4, 1997